Back

Genencell failed to pay more than half of COVID-19 trial fees

Verifying
  • Genencell failed to pay agreed clinical trial fees to three participating university hospitals.
  • Three hospitals reportedly received less than 100 million Korean won each.
  • Genencell halted ES16001 trials in 2023 after enrolling about 100 participants.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.